title: Patient considerations in the management of ulcerative colitis - role of vedolizumab.
abstract: Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6-24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn's disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific focus on the management of UC. Additionally, data on safety and the current UC management protocols are also discussed.
authors: Division of Gastroenterology and Hepatology, Lenox Hill Hospital-NSLIJ, New York, NY, USA.
authors: Megha
authors: M
authors: Kothari
authors: Division of Gastroenterology and Hepatology, Lenox Hill Hospital-NSLIJ, New York, NY, USA.
authors: Prashant
authors: P
authors: Mudireddy
authors: Division of Gastroenterology and Hepatology, Lenox Hill Hospital-NSLIJ, New York, NY, USA.
authors: Arun
authors: A
authors: Swaminath
keywords: immunomodulator drugs; inflammation; infliximab; mucosal healing; remission; ulcerative colitis